Recent studies have shown that HIV-1 replication in vivo occurs continuously at high levels 1;2 . Ho et al 1 found that when a protease inhibitor was administered to infected patients, plasma levels of HIV-1 decreased exponentially with a mean half-life (t 1=2 ) of 2:1 0:4 days. Wei et al 2 and Nowak et al 3 found essentially identical kinetics of viral decay following the use of inhibitors of HIV-1 protease or reverse transcriptase. The viral decay observed in these studies was a composite of two separate e ects: clearance of free virions from plasma and loss of virus-producing cells. To understand the kinetics of these two viral compartments more precisely, we monitored the viral load closely in ve HIV-1-infected subjects after the administration of a potent protease inhibitor. Using a mathematical model for viral dynamics and nonlinear least-squares tting of the data, separate estimates of the virion clearance rate, the infected cell lifespan, and the average viral generation time in vivo were obtained. Ritonavir 4;5 was administered orally (1200 mg/day) to ve infected patients, whose baseline characteristics are shown in Table 1 . Using an ultrasensitive modi cation 1;5 of the branched DNA assay 6;7 , HIV-1 RNA levels in plasma were measured after treatment at frequent intervals (every 2 hours until the sixth hour, every 6 hours until day 2, and every day until day 7). As shown in three examples in Figs. 1A and 1B, each patient responded with a similar pattern of viral decay, with an initial lag followed by an approximately exponential decline in plasma viral RNA.
After ritonavir was administered, a delay in its antiviral e ect was expected due to the time required for drug absorption, distribution, and penetration into the target cells.
This pharmacokinetic delay could be estimated by the time elapsed before the rst drop in the titer of infectious HIV-1 in plasma (Table 1 ; Fig. 1B ) However, even after the pharmacokinetic delay was accounted for, a lag of 1:25 days was observed before the plasma viral RNA fell (Fig. 1 ). This additional delay is consistent with the mechanism of action of protease inhibitors, which render newly produced virions non-infectious but inhibit neither the production of virions from already infected cells, nor the infection of new cells by previously produced infectious virions 8 .
In our previous study 1 , measurements were only taken every three days, so the delay in the fall of plasma RNA was missed. The results were tted to a single exponential, which was su cient to provide minimum estimates of HIV-1 kinetics. In contrast, in the present study, 15 data points were obtained during the rst seven days, allowing a careful analysis of the results using a new mathematical model of viral kinetics.
We assume HIV-1 infects target cells, T , with a rate constant k and causes them to become productively infected cells, T . Before drug treatment, the dynamics of cell infection and viral production are represented by (2) where V is the concentration of viral particles in plasma, is the rate of loss of infected cells, N is the number of new virions produced per infected cell during its lifetime, and c is the rate constant for viral clearance 9 . The loss of infected cells could be due to viral cytopathicity, immune elimination, or other processes such as apoptosis. Virion clearance could be due to binding and entry into cells, immune elimination, or nonspeci c removal by the reticuloendothelial system. We assume that ritonavir does not a ect the survival or rate of virion production of infected cells, and that after the pharmacological delay all newly produced virions are noninfectious. However, infectious virions produced before drug e ect are still present until they are cleared. Therefore, after treatment with ritonavir, dT dt = kV I T ? T ; (3) dV I dt = ?cV I ; (4) dV N I dt = N T ? cV N I ; (5) where V I is the plasma concentration of virions in the infectious pool (produced before drug e ect; V I (t = 0) = V 0 ), V N I is the concentration of virions in the non-infectious pool (produced after drug e ect; V N I (t = 0) = 0), and t = 0 is the time of onset of the drug e ect. In our analyses, it is assumed that viral inhibition by ritonavir is 100%, although the model can be generalized for non-perfect drugs 10 .
Assuming that the system is at quasi-steady state before drug treatment 11 , and that the uninfected cell concentration, T , remains at approximately its steady-state level, T 0 , for one week after drug administration 1;5 , we nd from Eqs. (3)- (5) (6) which di ers from the equation derived by Wei et al (2, see ref. 12 ). Allowing T to increase necessitates using numerical methods to predict V (t), but does not substantially alter the outcomes of the analyses given below 13 .
Using nonlinear regression analysis (Fig. 1, legend) , we estimated c, the viral clearance rate constant, and , the rate of loss of virus-producing cells, for each of the patients by tting Eq. (6) to the plasma HIV-1 RNA measurements (Table 1, ref 13 ). The theoretical curves generated from Eq. (6), using the best-t values of c and , gave an excellent t to the data for all patients (3 examples shown in Fig. 1 ).
Clearance of free virions is the more rapid process, occurring on a time scale of hours.
The values of c ranged from 2.06 to 3.81 day ?1 with a mean of 3:07 0:64 day ?1 ( Table 1 ).
The corresponding t 1=2 of free virions (t 1=2 = ln 2=c) ranged from 0.18 days to 0.34 days with a mean of 0:24 0:06 days ( 6 hours).
Con rmation of the virion clearance rate was obtained from an independent experiment that measured by quantitative cultures 14 the rate of loss of viral infectivity in plasma for patient 105 (Fig. 1B) . The loss of infectious virions occurred by rst-order decay, with a rate constant of 3:0 day ?1 , which is within the 68% con dence interval of the estimated c value for that patient ( Table 1) .
At steady state, the production rate of virus must equal its clearance rate, cV . Using the estimate of c and the pretreatment viral level, V 0 , we obtained an estimate for the rate of viral production before ritonavir administration. Estimating each patient's plasma and extracellular uid volumes based on body weight, the total daily viral production and clearance rates ranged from 0:4 10 9 to 32:1 10 9 virions per day, with a mean of 10:3 10 9 virions per day released into the extracellular uid (Table 1) Several features of the replication cycle of HIV-1 in vivo could be discerned from our analysis. Given that c and represent the decay rate constants for plasma virions and productively infected cells, respectively, then 1=c and 1= are the corresponding average lifespans of these two compartments. Thus, the average lifespan of a virion in the extracellular phase is 0:3 0:1 days, whereas the average lifespan of a productively infected cell is 2:2 0:8 days ( Table 2 ). The average generation time of the virus, , de ned as the time from release of a virion until it infects another cell and causes the release of a new generation of viral particles, should equal the sum of the average lifespan of a free virion and the average lifespan of a productively infected cell, or = 1=c + 1= , a relationship that can be shown formally ( Table 2 legend). Table 2 shows the average value of for the patients to be 2:6 0:8 days.
By a heuristic procedure, we can nd minimal estimates for the average duration of the HIV-1 life cycle and its intracellular or eclipse phase (from virion binding to the release of the rst progeny). We estimate the duration of the HIV-1 life cycle, S, de ned as the duration from release of a virion until the release of its rst progeny virus, by the lag in the decay of HIV-1 RNA in plasma (Fig. 1) after the pharmacologic delay (Table 1) has been subtracted. The shoulder in the RNA decay curve is explained by the fact that virions produced before the pharmacologic e ect of ritonavir are still infectious and capable of producing, for a single cycle, viral particles that would be detected by the RNA assay.
Thus, the fall in the RNA level should begin when target cells interact with drug-a ected virions and do not produce new virions. These \missing virions" would rst have been produced at a time equal to the minimum time for infection plus the minimum time for production of new progeny. As shown in Table 2 , the estimated values for S were quite consistent for the ve patients, with a mean duration of 1:2 0:1 days. In steady state, 1=c = 1=NkT 0 is the average time for infection (Table 2, legend). Assuming this average time is greater than the minimal time for infection, S ?1=c = 0:9 day, is a minimal estimate of the average duration of the intracellular phase of the HIV-1 life cycle 17 .
Using potent antiretroviral agents to perturb the quasi-steady state in vivo, previous studies provided a crude estimate of the t 1=2 of viral decay in which the lifespan of productively infected cells could not be separated from that of plasma virions (1,2). Here, using a new mathematical model to analyze a detailed set of data collected after the administration of a protease inhibitor, we have determined the average lifespan of a productively infected cell (presumably an activated CD4 lymphocyte) to be 2.2 days. Thus, such cells are lost with an average t 1=2 of 1.6 days (Fig. 2) . Note that the lifespans of productively infected cells are not dramatically di erent among the study subjects (Table 2) , even though patients with low CD4 lymphocyte counts generally have decreased numbers of virus-speci c, MHC class I-restricted cytotoxic T lymphocytes 18 .
The average lifespan of a virion in blood was calculated to be 0.3 days. Therefore, a population of plasma virions is cleared with a t 1=2 of 0.24 days, i.e., on average, half of the plasma virions turns over approximately every 6 hours (Fig. 2) . Because our analysis assumed that the antiviral e ect of ritonavir was complete and that target cells did not recover during treatment, our estimates of the virion clearance rate and infected cell loss rate are minimal estimates 13;17 . Consequently, the true virion t 1=2 may be shorter than 6 hours. For example, Nathanson and Harrington 19 found that monkeys clear the Langat virus from their circulation on a time scale of about 30 minutes. Thus, the total number of virions produced and released into the extracellular uid is at least 10:3 10 9 particles per day 15 , which is about 15-fold higher than our previous minimum estimate (1). At least 99% of this large pool of virus is produced by recently infected cells (1,2) (Fig. 2) .
At quasi-steady state viral clearance, cV , equals viral production, N T . Because c has similar values for all patients studied (Table 1) Co n has cogently argued that on average every mutation at every position in the genome would occur numerous times each day 20 . The larger turnover rate of HIV-1 described in the present study only makes this type of consideration even more applicable. Therefore, the failure of the current generation of antiviral agents, when used as monotherapy, is the inevitable consequence of the dynamics of HIV-1 replication. E ective treatment must, instead, force the virus to mutate simultaneously at multiple positions in one viral genome by using a combination of multiple, potent antiretroviral agents. Moreover, that the process of producing mutant viruses is repeated for 140 generations each year argues strongly for aggressive therapeutic intervention early if a dramatic clinical impact is to be achieved 22 . Third, from the current study and previous reports (1,2,5), it is now clear that the 12. Equation (6) (1) and (2) and the assumption that no new infections occur after drug treatment (k = 0 after treatment). Equation (6) 13. Because our parameter estimates are based on the assumption of complete inhibition of the production of new infectious virions and no increase in target cells, we expect that our parameter estimates to be minimal estimates. Generalizing our model to relax these two assumptions, we can show that is always a minimal estimate and that with target cell growth c, typically, is also a minimal estimate. We tested how the estimates of c and depend on the assumption that ritonavir is 100% e ective as follows: We generated viral load data assuming di erent drug e ectivenesses with c = 3 and = 0:5. With this \data" we used our tting procedure to estimate c and under the assumption that the drug is 100% e ective. For data generated with Table 1 are minimal estimates. Increasing c, will decrease 1=c, and increase the estimate, S ? 1=c, of the intracellular delay. Thus, the duration of the intracellular phase, as derived in the text and given in Table 2 , is still a minimal estimate. (6) to the data. The parameters, c, viral clearance rate, , the rate of loss of infected cells, and V 0 , the initial viral load, were simultaneously estimated. To account for the pharmacokinetic delay, t = 0 in Eq. (6) was assumed to correspond to the time of the pharmacokinetic delay (if measured) or was chosen as the best t value among 2, 4, and 6 hours (see Table 1 ). The logarithm of the experimental data was tted to the logarithm of Eq. (6) 3), with the initial condition T (0) = 0. At any given time, t, the mean number of virions produced from the initial V 0 virions is V N I (t) = P (t)V 0 , where P (t) is the (cumulative) probability that a virion is produced by time t. The probability density of a virus being produced at time t is p(t) = dP=dt, and thus the average time of virion production = 
